Context Therapeutics Inc.
CNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22,701 | $17,783 | $7,091 | $3,805 |
| G&A Expenses | $7,223 | $7,290 | $7,790 | $3,633 |
| SG&A Expenses | $7,223 | $7,290 | $7,790 | $3,633 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $500 | $3,088 |
| Operating Expenses | $29,924 | $25,073 | $15,381 | $10,526 |
| Operating Income | -$29,924 | -$25,073 | -$15,381 | -$10,526 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,199 | $1,108 | $545 | $69 |
| Pre-Tax Income | -$26,725 | -$23,964 | -$14,836 | -$10,457 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26,725 | -$23,964 | -$14,836 | -$10,457 |
| % Margin | – | – | – | – |
| EPS | -0.46 | -1.5 | -0.93 | -3.69 |
| % Growth | 69.3% | -61.3% | 74.8% | – |
| EPS Diluted | -0.46 | -1.5 | -0.93 | -3.69 |
| Weighted Avg Shares Out | 58,416 | 15,966 | 15,966 | 2,834 |
| Weighted Avg Shares Out Dil | 58,416 | 15,966 | 15,966 | 2,834 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,200 | $1,164 | $547 | $0 |
| Interest Expense | $0 | $0 | $547 | $64 |
| Depreciation & Amortization | $11 | $12 | $9 | $0 |
| EBITDA | -$29,913 | -$25,061 | -$14,872 | -$10,393 |
| % Margin | – | – | – | – |